b9d1 Antibody

What is B9D1 and why is it an important research target?

B9D1 is a B9 domain-containing protein that functions as a component of the "tectonic-like complex" localized at the transition zone of primary cilia. This complex acts as a barrier preventing diffusion of transmembrane proteins between cilia and plasma membranes . B9D1 is required for ciliogenesis and proper Sonic Hedgehog (SHH) signaling pathways . The gene is located within the Smith-Magenis syndrome region on chromosome 17p11.2 .

B9D1 has garnered significant research interest because mutations in this gene have been associated with Meckel syndrome (MKS9) and Joubert syndrome 27 (JBTS27) , which are rare autosomal recessive ciliopathies characterized by developmental abnormalities. The protein forms a crucial complex with MKS1 and B9D2, making it an important target for understanding ciliary biology and ciliopathy pathogenesis .

What applications are B9D1 antibodies commonly validated for?

B9D1 antibodies have been validated for multiple experimental applications:

The specific applications vary by antibody source and clone. Validation data typically includes detection in human, mouse, and rat samples , with many antibodies showing cross-reactivity among these species. When selecting an antibody, researchers should consider the specific validated applications for their experimental system .

What species reactivity should I consider when selecting a B9D1 antibody?

When selecting a B9D1 antibody, species reactivity is a crucial consideration for experimental design. Available B9D1 antibodies demonstrate varied species reactivity profiles:

• Human-specific: Several commercially available antibodies are validated only for human B9D1 detection

• Multi-species: Some antibodies show verified reactivity against human, mouse, and rat B9D1

When working with non-human model systems, researchers should:

• Verify sequence homology between the immunogen and the target species' B9D1 protein

• Perform preliminary validation tests in their specific experimental system

• Consider species-specific positive controls when assessing antibody performance

How should B9D1 antibodies be stored to maintain their efficacy?

Proper storage of B9D1 antibodies is essential for maintaining their efficacy and extending their usable lifespan. Based on manufacturer recommendations:

• Long-term storage: Store antibodies at -20°C in aliquots to avoid repeated freeze-thaw cycles . Some suppliers specifically recommend avoiding repeated freeze-thaw cycles as this can lead to denaturation and loss of binding activity .

• Buffer conditions: Most B9D1 antibodies are supplied in PBS (pH 7.3) containing:

  • 50% glycerol as a cryoprotectant

  • 0.02% sodium azide as a preservative

• Shipping conditions: These antibodies are typically shipped on wet ice or with polar packs and should be stored immediately upon receipt .

• Working solutions: When preparing diluted working solutions, store at 4°C for short-term use (1-2 weeks).

• Aliquoting recommendation: Upon receiving a new B9D1 antibody, divide it into small single-use aliquots before freezing to minimize freeze-thaw cycles and maintain antibody performance .

How can I optimize detection of B9D1 at the ciliary transition zone?

Detecting B9D1 at the ciliary transition zone presents several technical challenges due to its specific subcellular localization. Based on research methodologies:

• Fixation protocol optimization:

  • For immunofluorescence, use 4% paraformaldehyde fixation followed by permeabilization with 0.1-0.2% Triton X-100

  • Avoid methanol fixation which can disrupt ciliary structures

• Co-localization markers:

  • Use established ciliary markers (e.g., acetylated α-tubulin for the axoneme, γ-tubulin for basal bodies)

  • Consider co-staining with other transition zone proteins like MKS1 or B9D2

• Cell types and conditions:

  • Optimal detection occurs in ciliated cell types like RPE1 cells with well-formed primary cilia

  • Serum starvation (24-48 hours) enhances ciliogenesis and improves detection

  • For tissues, kidney sections often show robust ciliary staining

• Antibody considerations:

  • Use dilutions at the lower end of the recommended range (e.g., 1:50-1:100) for transition zone detection

  • Consider using tyramide signal amplification for enhanced sensitivity

  • Longer primary antibody incubation (overnight at 4°C) may improve detection

• Technical challenges:

  • Commercial antibodies show variable efficiency for immunofluorescence detection of endogenous B9D1 at the transition zone

  • Consider using epitope-tagged constructs (e.g., EGFP-B9D1) for localization studies when antibody detection is suboptimal

Researchers have observed that the interdependence of B9D proteins affects their localization; B9D1 fails to localize to the transition zone in B9D2 or MKS1 knockout cells, suggesting the entire complex is necessary for proper localization .

What controls should be included when studying B9D1-MKS1-B9D2 complex formation?

When investigating the B9D1-MKS1-B9D2 complex formation, appropriate controls are essential for experimental validity and data interpretation:

• Knockout/knockdown controls:

  • Use CRISPR/Cas9-generated B9D1, B9D2, or MKS1 knockout cell lines as negative controls

  • siRNA-mediated knockdown can serve as an alternative approach

  • Validate knockout/knockdown efficiency by immunoblotting

• Protein interaction controls:

  • For co-immunoprecipitation studies:

    • Include IgG control to assess non-specific binding

    • Test individual protein components (B9D1 alone, B9D2 alone, MKS1 alone)

    • Validate the linear interaction model (MKS1-B9D2-B9D1) using visible immunoprecipitation (VIP) or visible three-hybrid assays

• Truncation/domain mutation controls:

  • Test B9D deletion mutants to confirm domain-specific interactions

  • MKS1 truncation mutants have demonstrated that:

    • N-terminal truncation mutants MKS1(110-559) and MKS1(290-559) retain B9D2 binding

    • MKS1(311-559) loses this ability

    • C-terminal truncation mutant MKS1(1-492) lacks B9D2 binding

• Cross-validation techniques:

  • Combine multiple interaction detection methods:

    • Direct visualization using VIP assay

    • Biochemical validation by immunoblotting

    • In vivo confirmation through fluorescence microscopy

• Biological function assessment:

  • Examine ciliogenesis efficiency in cells with disrupted complex formation

  • Assess ciliary membrane protein localization as a functional readout of transition zone integrity

  • Measure Hedgehog signaling activity as a downstream functional consequence

The linear interaction model of MKS1-B9D2-B9D1 has been demonstrated where B9D2 interacts directly with both MKS1 and B9D1, while MKS1 and B9D1 do not directly interact with each other . This architecture must be considered when designing appropriate controls.

How can I distinguish between different isoforms of B9D1 using antibodies?

Distinguishing between B9D1 isoforms presents a specific challenge in research applications. Current knowledge indicates at least two isoforms of B9D1 exist , which affects experimental design and antibody selection:

• Isoform-specific considerations:

  • Most commercial antibodies recognize only the longest B9D1 isoform

  • When studying specific isoforms, verify which isoform(s) your antibody detects by reviewing the immunogen sequence

• Western blot optimization:

  • Use high-resolution SDS-PAGE (12-15% gels) to separate closely sized isoforms

  • Include positive controls with known isoform expression patterns

  • Consider using gradient gels for better separation of lower molecular weight isoforms

  • Expected molecular weight of the primary isoform is approximately 16.9 kDa

• Epitope mapping strategies:

  • Select antibodies raised against different regions:

    • N-terminal antibodies (amino acids 1-130) are common

    • C-terminal antibodies may help distinguish certain isoforms

  • For studies requiring isoform differentiation, consider using multiple antibodies targeting different epitopes

• Validation approaches:

  • Recombinant expression of individual isoforms as positive controls

  • siRNA targeting specific isoforms can help confirm antibody specificity

  • For critical studies, consider mass spectrometry validation of detected bands

• Technical considerations:

  • Some antibodies, like those from SAB (SAB1409114), specifically note detection of the 16.9 kDa antigen

  • The antibody from Signalway Antibody explicitly states it "will only recognize the longest isoform" and "is predicted to not cross-react with other DNAJC family members"

When absolute isoform specificity is required, researchers might need to develop custom antibodies against unique regions of specific B9D1 isoforms or employ genetic tagging approaches.

What considerations are important when using B9D1 antibodies for studying ciliopathy disease models?

When studying ciliopathy disease models with B9D1 antibodies, researchers should consider several critical factors:

• Disease-relevant mutations:

  • B9D1 mutations have been identified in:

    • Meckel syndrome 9 (MKS9)

    • Joubert syndrome 27 (JBTS27)

  • Consider using antibodies that can detect mutant forms relevant to your disease model

  • Splice-donor site mutations in B9D1 have been detected in MKS patients

• Model system selection:

  • Cell models: RPE1 cells are commonly used for studying ciliary transition zone proteins

  • Animal models: Mouse, rat, and C. elegans have been used to study B9D1 function

  • Patient-derived cells provide the most disease-relevant context

• Complex formation assessment:

  • B9D1 functions in complex with MKS1 and B9D2

  • Disease mutations may affect complex formation rather than protein expression

  • Use co-immunoprecipitation or VIP assays to assess complex integrity in disease models

• Functional readouts:

  • Ciliogenesis defects (primary cilium formation)

  • Hedgehog signaling abnormalities

  • Diffusion barrier function at the transition zone

  • Developmental phenotypes in animal models

• Technical optimizations:

  • For tissues with ciliopathy phenotypes (kidney, brain, liver), optimize immunohistochemistry protocols:

    • Recommended dilutions: 1:50-1:200 for IHC

    • Antigen retrieval may improve detection in fixed tissues

  • For cultured cells, immunofluorescence works well at 1:50-1:200 dilutions

• Genetic background considerations:

  • Genetic modifiers may influence phenotype severity

  • Confirm B9D1 antibody specificity in your genetic background

  • Consider the influence of other ciliopathy gene mutations in your model

The formation of the B9D1-B9D2-MKS1 complex is crucial for creating a diffusion barrier for ciliary membrane proteins, and disruption of this complex is directly linked to ciliopathy manifestations , making it an important target for mechanistic studies.

What are the latest approaches for developing highly specific B9D1 antibodies?

Recent advances in antibody development technologies offer new approaches for creating highly specific B9D1 antibodies:

• Computational design strategies:

  • Biophysics-informed models can be used to design antibodies with customized specificity profiles

  • Machine learning approaches identify specific binding modes associated with particular ligands

  • These computational methods can:

    • Generate antibody variants not present in initial libraries

    • Predict binding outcomes for new ligand combinations

    • Create antibodies with either specific high affinity for particular targets or cross-specificity for multiple targets

• Epitope selection optimization:

  • Target unique regions of B9D1 not shared with related proteins

  • Common immunogens include:

    • Recombinant fusion proteins corresponding to amino acids 1-130 of human B9D1 (NP_056496.1)

    • 18 amino acid peptides near the C-terminus of human B9D1

  • Structural analysis of the B9 domain can inform epitope selection strategies

• Validation methodologies:

  • High-throughput sequencing combined with computational analysis improves specificity validation

  • Phage display experiments against various combinations of ligands can identify optimal binders

  • Cross-validation against potential cross-reactive proteins:

    • B9D2 (structurally similar B9 domain protein)

    • Other ciliary transition zone proteins

• Affinity maturation techniques:

  • Directed evolution approaches through multiple rounds of selection

  • Targeted mutagenesis of complementarity-determining regions (CDRs)

  • Selection pressure utilizing both positive and negative targets to enhance specificity

• Advanced purification methods:

  • Most B9D1 antibodies undergo affinity purification:

    • Using peptide columns

    • Affinity chromatography

  • Cross-adsorption against related proteins can improve specificity

Research has demonstrated that combining biophysics-informed modeling with extensive selection experiments provides a powerful approach for designing proteins with desired binding properties, applicable to antibody development beyond just B9D1 .

How can I optimize Western blot protocols for B9D1 detection?

Optimizing Western blot protocols for B9D1 detection requires attention to several key factors:

• Protein extraction considerations:

  • Use RIPA buffer with protease inhibitors for effective extraction

  • B9D1 is found in ciliary transition zones, which can be difficult to solubilize

  • Consider subcellular fractionation for enrichment of ciliary proteins

• Sample preparation and loading:

  • Load adequate protein (25-50 μg per lane)

  • Heat samples at 95°C for 5 minutes in reducing sample buffer

  • B9D1 has a molecular weight of approximately 16.9 kDa

• Gel selection and transfer conditions:

  • Use 12-15% SDS-PAGE gels for optimal separation

  • Consider gradient gels (4-20%) for simultaneous detection of B9D1 and its interaction partners

  • Use PVDF membranes and optimize transfer conditions for low molecular weight proteins

  • Semi-dry transfer systems work well for proteins of this size

• Antibody conditions:

  • Recommended dilutions: 1:500-1:2000 or 1 μg/mL

  • Primary antibody incubation: overnight at 4°C for optimal results

  • Secondary antibody: HRP-conjugated anti-rabbit IgG at 1:10,000 dilution

  • 3% non-fat dry milk in TBST works well as blocking buffer

• Detection system:

  • Enhanced chemiluminescence (ECL) detection systems provide sufficient sensitivity

  • Typical exposure times range from 90 seconds to several minutes

  • Consider using signal enhancer solutions for weak signals

• Controls and validation:

  • Positive controls: extracts from cells known to express B9D1

  • Negative controls: B9D1 knockout cell lysates if available

  • B9D1 has been successfully detected in various cell lines

The Western blot protocol used in validation studies demonstrated successful detection with 25 μg protein per lane, 1:1000 dilution of primary antibody, and 90-second exposure time with standard ECL detection .

What are the key considerations for validating B9D1 antibody specificity?

Thorough validation of B9D1 antibody specificity is critical for experimental reliability and reproducibility:

• Genetic validation approaches:

  • CRISPR/Cas9 knockout cell lines provide definitive negative controls

  • siRNA knockdown can demonstrate signal reduction corresponding to protein depletion

  • Overexpression systems can confirm signal increase with elevated B9D1 levels

• Cross-reactivity assessment:

  • Test against related proteins (particularly B9D2)

  • Some vendors note that their B9D1 antibodies "will not cross-react with other DNAJC family members"

  • Check for unexpected bands in Western blots that might indicate cross-reactivity

• Multi-application validation:

  • Verify consistency across different applications (WB, IHC, IF)

  • Application-specific controls should be included:

    • For IHC: peptide blocking experiments

    • For IF: co-localization with known ciliary markers

    • For WB: molecular weight confirmation

• Epitope mapping considerations:

  • Understand the specific region targeted by your antibody

  • Common epitopes include:

    • N-terminal regions (amino acids 1-130)

    • C-terminal peptides

  • Consider using multiple antibodies targeting different epitopes for confirmation

• Bioinformatic analysis:

  • BLAST searches of immunogen sequences to identify potential cross-reactive proteins

  • Protein structure analysis to identify exposed epitopes

  • Alternative splicing assessment to understand which isoforms might be detected

• Quantitative validation metrics:

  • Signal-to-noise ratio in different applications

  • Dose-response relationship with varying antigen concentrations

  • Reproducibility across different lots of the same antibody

For thorough validation, researchers can consider using independent antibodies from different vendors (e.g., Bio-Techne (NBP2-92821) , Signalway Antibody , Sigma-Aldrich (HPA022957) ) to confirm findings through multiple reagents.

How can I use B9D1 antibodies to study ciliary transition zone formation?

B9D1 antibodies are valuable tools for investigating ciliary transition zone formation, particularly when used in combination with other methodologies:

• Temporal studies of transition zone assembly:

  • Track B9D1 localization during ciliogenesis using time-course immunofluorescence

  • Use inducible expression systems to monitor transition zone formation in real-time

  • Synchronized cell systems can reveal the sequence of protein recruitment

• Spatial organization analysis:

  • Super-resolution microscopy (STED, STORM, SIM) using B9D1 antibodies can reveal detailed organization

  • Co-staining recommendations:

    • Basal body markers (γ-tubulin, centrin)

    • Axoneme markers (acetylated α-tubulin)

    • Other transition zone proteins (MKS1, B9D2, NPHP module proteins)

  • Immunogold electron microscopy for ultrastructural localization

• Protein complex dynamics:

  • Proximity ligation assays (PLA) to visualize B9D1 interactions in situ

  • FRAP (Fluorescence Recovery After Photobleaching) with tagged B9D1 to assess mobility

  • B9D1 antibodies in immunoprecipitation studies to identify novel interaction partners

• Functional manipulation studies:

  • Use B9D1 antibodies to monitor transition zone integrity after:

    • Microtubule disruption (nocodazole, cold treatment)

    • Actin cytoskeleton perturbation (cytochalasin D)

    • Cell cycle manipulation

  • Assess changes in B9D1 localization during ciliary resorption

• Developmental and tissue-specific analyses:

  • IHC with B9D1 antibodies (dilutions 1:50-1:200) in developing tissues

  • Compare transition zone composition across different ciliated tissues

  • Assess changes in disease models (kidney, brain, retina)

• Technical implementation:

  • Immunofluorescence protocols:

    • 4% PFA fixation

    • 0.1-0.2% Triton X-100 permeabilization

    • Antibody dilutions: 1:50-1:200

    • Optimal visualization with confocal microscopy

Research has demonstrated that the TZ localization of B9D1 depends on both B9D2 and MKS1, indicating the interdependence of these three B9D proteins in transition zone formation . When studying transition zone formation, this interdependence must be considered in experimental design and interpretation.

How do different commercially available B9D1 antibodies compare in performance?

When selecting a B9D1 antibody for research, understanding performance differences between commercial options is crucial:

Performance considerations:

• Application-specific performance:

  • For Western blot: Bio-Techne/Novus (NBP2-92821) shows validated results with clear bands at expected molecular weight

  • For immunofluorescence: Bio-Techne/Novus antibody demonstrates clear ciliary localization

  • For IHC: Sigma-Aldrich (HPA022957) offers extensive tissue validation through Human Protein Atlas

• Species reactivity differences:

  • Multi-species reactivity (human, mouse, rat): Bio-Techne/Novus (NBP2-92821)

  • Human-specific: Signalway Antibody, Sigma-Aldrich (HPA022957)

• Epitope considerations:

  • N-terminal targeting: Bio-Techne/Novus, Abbexa

  • C-terminal targeting: Signalway Antibody

  • Different epitopes may perform differently depending on protein conformation or interactions

• Validation depth:

  • Human Protein Atlas antibodies (Sigma HPA022957) undergo extensive tissue array validation (44 normal human tissues)

  • Bio-Techne provides multiple validation images across applications

  • Antibodypedia lists top validated antibodies including LSBio (LS-C409517), antibodies-online (ABIN1450121), and GeneTex (GTX32055)

When considering which antibody to use, researchers should prioritize those with validation data most relevant to their specific application, experimental system, and research question.

How can I use B9D1 antibodies to investigate ciliopathy disease mechanisms?

B9D1 antibodies serve as valuable tools for investigating ciliopathy disease mechanisms through multiple experimental approaches:

• Patient sample analysis:

  • Examine B9D1 protein expression and localization in:

    • Patient-derived fibroblasts

    • Induced pluripotent stem cells (iPSCs)

    • Tissue biopsies when available

  • Compare ciliary transition zone architecture between patient and control samples

• Genotype-phenotype correlation studies:

  • Analyze B9D1 expression in samples with different B9D1 mutations:

    • Splice-donor site mutations identified in MKS patients

    • Mutations associated with Joubert syndrome

  • Assess whether mutations affect protein stability, localization, or complex formation

• Molecular pathway analysis:

  • Investigate downstream signaling effects using B9D1 antibodies:

    • Hedgehog pathway components (immunoblotting, co-IP)

    • Ciliary membrane protein diffusion (IF)

    • Ciliary protein trafficking (live imaging with IF validation)

• Complex formation assessment:

  • Using co-immunoprecipitation with B9D1 antibodies:

    • Examine MKS1-B9D2-B9D1 complex integrity

    • Identify altered interaction partners in disease states

    • Quantify complex formation efficiency

• Functional rescue experiments:

  • Monitor transition zone restoration after genetic rescue:

    • Use B9D1 antibodies to confirm proper localization of reintroduced wild-type or mutant B9D1

    • Assess correction of ciliary phenotypes

    • Quantify transition zone protein composition

• Model system validation:

  • Confirm disease relevance of animal or cell models:

    • Verify that B9D1 expression/localization defects match patient findings

    • Validate phenotypes across multiple model systems

    • Establish correlation between molecular and morphological phenotypes

The interdependence of B9D proteins for transition zone localization makes B9D1 antibodies particularly useful for studying how mutations in any complex member (MKS1, B9D2, or B9D1) might disrupt the entire complex and lead to ciliopathy phenotypes .

What emerging technologies enhance B9D1 antibody-based research?

Several emerging technologies are enhancing the capabilities and applications of B9D1 antibody-based research:

• Advanced imaging techniques:

  • Super-resolution microscopy (STORM, STED, SIM) enables visualization of B9D1 within the ciliary transition zone at near-molecular resolution

  • Expansion microscopy physically enlarges specimens, making transition zone architecture more accessible for standard confocal microscopy

  • Light-sheet microscopy allows for rapid 3D imaging of B9D1 in developing tissues or organoids

• Proximity-based protein interaction methods:

  • BioID or TurboID proximity labeling with B9D1 as bait identifies neighboring proteins

  • Proximity ligation assay (PLA) visualizes B9D1 interactions with specific partners in situ

  • APEX2-based proximity labeling for electron microscopy can reveal ultrastructural context

• Biophysics-informed computational design:

  • Machine learning approaches predict antibody binding specificity profiles

  • Computational models disentangle binding modes associated with specific ligands

  • These methods enable:

    • Design of antibodies with customized specificity beyond experimental libraries

    • Prediction of cross-reactivity

    • Generation of antibodies with precisely defined binding properties

• Single-cell technologies:

  • Single-cell proteomics to analyze B9D1 expression heterogeneity

  • Multiplexed antibody-based imaging (CODEX, CycIF) for simultaneous detection of multiple ciliary proteins

  • Spatial transcriptomics combined with B9D1 antibody staining to correlate protein localization with gene expression

• CRISPR-based genomic tagging:

  • Precise endogenous tagging of B9D1 for live-cell imaging

  • Split-GFP complementation systems to visualize B9D1 interactions

  • Degradation tagging (AID/dTAG) systems for acute B9D1 depletion combined with antibody-based readouts

• Microfluidic and organ-on-chip platforms:

  • Microfluidic devices with ciliated cells allow controlled flow conditions while monitoring B9D1 localization

  • Organ-on-chip platforms (kidney, brain) provide physiologically relevant contexts for studying B9D1 in ciliopathies